DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status.

Furthermore, the pCR rate in TNBC (4 of 14 patients, 29%) and LowHR TNBC-like samples (3 of 10 patients, 30%) was lower than in LowHR HRpos-like cases (9 of 13 patients, 69%), although this difference had only borderline significance ( p = 0.05 and p = 0.09; Fig. 4 b).

also in 7,017 other papers